The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.

ABSTRACT:

Background

A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.

Methods

Applying the mendelian randomisation principle, we used single nucleotide polymorphisms (SNPs) in the gene IL6R to evaluate the likely efficacy and safety of IL6R inhibition for primary prevention of coronary heart disease. We compared genetic findings with the effects of tocilizumab reported in randomised trials in patients with rheumatoid arthritis.

Findings

In 40 studies inclu

SUBMITTER: Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium 

PROVIDER: S-EPMC3316968 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature